



## Gut Dysbiosis: Molecular Mechanisms and Therapies 2.0

Guest Editors:

**Dr. Federica Laudisi**

Department of Systems Medicine,  
University of Rome “Tor Vergata”,  
Rome, Italy

**Dr. Carmine Stolfi**

Department of Systems Medicine,  
University of Rome “Tor Vergata”,  
00133 Rome, Italy

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editors

Gut dysbiosis—characterized by a reduction in microbial diversity, decreased frequency of beneficial bacterial strains and overgrowth of pathobionts—frequently associates with the development of intestinal and extra-intestinal disorders. Many environmental factors (including diet, drugs and stress) can trigger gut dysbiosis by altering the complex interaction between microbial ecology and the host immune system, thereby promoting intestinal epithelial barrier dysfunctions that may ultimately lead to the development of several pathological conditions.

We invite researchers working on gut dysbiosis to submit original articles or reviews to improve our knowledge on this complex and fascinating field.

- Role of dysbiotic microbiota and microbial metabolites in gut homeostasis, intestinal barrier function and host immune system;
- Contribution of gut dysbiosis to the development of intestinal (e.g., inflammatory bowel diseases, colorectal cancer) and extra-intestinal disorders (e.g., neurological disorders, diabetes);
- Therapeutic strategies for gut microbiota modulation in pathological conditions (e.g., probiotic treatment, fecal microbiota transplantation).





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)